Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Symptoms and Progression: Mapping the Journey

At a Glance

PRKAR1B-related neurodegeneration and NIFID can cause stiffness, slowed movement, balance and swallowing problems, along with changes in behavior, planning, and attention. The course varies widely, so tracking falls, nutrition, mood, sleep, and daily function with a care team is important.

Because PRKAR1B-related neurodegeneration and Neuronal Intermediate Filament Inclusion Disease (NIFID) are ultra-rare, there is no single “typical” journey. However, researchers have identified a cluster of symptoms that often overlap, combining features of dementia (thinking and memory changes) and parkinsonism (movement challenges) [1][2]. It is important to know that not every patient will experience every symptom, and sudden changes should always be evaluated by a doctor.

The Movement Spectrum: Parkinsonism and Beyond

In many case reports, the physical symptoms are reported as the first to be noticed. These often fall under the umbrella of parkinsonism, which is a group of movement disorders that mimic Parkinson’s disease but are caused by different underlying pathology [3].

  • Rigidity and Slowness: You may experience rigidity (muscle stiffness) and bradykinesia (extreme slowness of movement). This can make daily tasks like buttoning a shirt or getting out of a chair feel increasingly difficult [1].
  • Gait and Balance: Changes in walking, such as a shorter stride or a feeling of “heaviness” in the legs, are common. Over time, this can lead to an increased risk of falls [4].
  • Pyramidal Signs: Some patients with NIFID-like pathology also develop “upper motor neuron” (pyramidal) signs, such as spasticity (unusually tight or stiff muscles) and exaggerated reflexes. This is not motor-neuron disease (like ALS) [5][6].
  • Bulbar Symptoms: This refers to the muscles used for speaking and swallowing. You may notice dysarthria (slurred or slow speech) or dysphagia (difficulty swallowing), which requires careful monitoring by your care team to prevent choking or pneumonia [6][7].

The Cognitive and Behavioral Spectrum

The “dementia” component of this diagnosis often resembles Frontotemporal Dementia (FTD), which affects the parts of the brain responsible for personality, behavior, and language [8][9].

  • Behavioral Changes: Symptoms similar to behavioral-variant FTD (bvFTD) may occur. This might manifest as apathy (loss of interest), impulsivity, or changes in how you relate to others socially [2].
  • Cognitive Decline: While memory may remain relatively intact early on, executive function (the ability to plan, organize, and multi-task) often declines. You may find it harder to follow complex instructions or manage finances [2][9].
  • Fluctuating Attention: Some patients experience periods where they seem very “with it” followed by periods of confusion or intense fatigue [10].

Disease Course and Progression

It is important to understand that the “clock” for this condition runs differently for everyone. In documented cases, the duration from the first symptom to late-stage disease has ranged from roughly 7 years to more than 16 years. However, these estimates appear to come from very small and potentially heterogeneous case reports and cannot reliably predict an individual course [5][6].

  1. Early Phase: Symptoms often start subtly—perhaps a slight tremor, a change in gait, or a shift in personality. At this stage, the focus is on maintaining independence and setting up a specialized care team [11].
  2. Middle Phase: Movement symptoms like stiffness and slowness typically become more prominent, and cognitive changes may begin to interfere with daily activities. You may require physical therapy or medications to manage parkinsonism [4][12].
  3. Advanced Phase: In later stages, speech and swallowing often become more difficult, and the need for assistance with all “Activities of Daily Living” (like bathing and dressing) increases. Mobility may become significantly limited, requiring a wheelchair or other assistive devices [6][13].

What to Monitor with Your Care Team

In such a rare condition, you and your caregiver are essential partners in observing changes. You should track and report the following to your neurologist:

  • Swallowing and Nutrition: Coughing while eating, a “wet” sounding voice after drinking, or unexplained weight loss are signals that a swallowing evaluation by a speech-language pathologist is needed [7][13]. Do not change food textures without professional guidance.
  • Safety and Falls: Keep a log of any “near misses” or actual falls to help your physical therapist adjust your mobility plan [4].
  • Mood and Sleep: Significant changes in mood, hallucinations (seeing things that aren’t there), or acting out dreams while asleep can sometimes occur and can often be managed with specific treatments [10][14].
  • Caregiver Strain: Because the combination of movement and cognitive symptoms is complex, caregivers often face high levels of stress. Discussing support options like respite care early can help prevent burnout [14].

URGENT WARNING SIGNS: Seek immediate emergency care for choking or sudden severe breathing difficulty, a fall resulting in a head injury or inability to stand, or sudden, severe confusion or new intense hallucinations (which may indicate a dangerous medication reaction or acute infection like a UTI).

Common questions in this guide

What symptoms can PRKAR1B-related neurodegeneration and NIFID cause first?
The first signs vary. Some people first develop movement changes such as stiffness, slowness, tremor, or a change in walking, while others notice personality, behavior, or planning problems. Not everyone develops every symptom, and sudden changes should be assessed by a clinician.
How can this condition affect movement?
It can cause muscle stiffness, very slow movement, shorter steps, balance problems, and falls. Some people also develop tight muscles and overactive reflexes, along with speech or swallowing difficulty. These movement problems can resemble Parkinson’s disease but have a different underlying cause.
What thinking and behavior changes may occur?
People may become less interested, more impulsive, or socially different. Planning, organizing, multitasking, and following complex instructions can become harder, while memory may be less affected early on. Attention can vary, with periods of alertness followed by confusion or fatigue.
How does PRKAR1B-related neurodegeneration usually progress?
The course varies widely from person to person. Reported cases have lasted about 7 years to more than 16 years from the first symptoms to late-stage disease, but these small reports cannot predict an individual’s course. Early symptoms may be subtle, middle stages can interfere with daily activities, and advanced stages may require help with mobility, speech, swallowing, and personal care.
What are warning signs of swallowing difficulty?
Coughing during meals, a wet-sounding voice after drinking, or unexplained weight loss can signal a swallowing problem. Tell the care team so a speech-language pathologist can assess swallowing, and do not change food textures without professional guidance. Choking or severe breathing difficulty requires emergency care.
When should someone with this condition receive emergency care?
Seek emergency help for choking, sudden severe breathing difficulty, a fall causing a head injury or inability to stand, or sudden severe confusion or new intense hallucinations. These symptoms may signal an immediate injury, infection, or dangerous medication reaction.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on PRKAR1B-related neurodegenerative dementia with intermediate filaments.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which symptom appeared first—cognitive changes or movement difficulties—and how does that help categorize this condition?
  2. 2.How do you expect the parkinsonism symptoms (stiffness, slowness) to respond to standard off-label medications like levodopa?
  3. 3.Given the pathology, should we be looking for signs of both frontal lobe changes (behavior) and pyramidal signs (spasticity)?
  4. 4.What is the best way to monitor for swallowing difficulties (dysphagia) as the disease progresses?
  5. 5.Are there specific 'milestones' we should watch for that would indicate a change in the level of care needed at home?

References

References (14)
  1. 1

    Allosteric modulation of protein kinase A in individuals affected by NLPD-PKA, a neurodegenerative disease in which the PRKAR1B L50R variant is expressed.

    Benjamin-Zukerman T, Pane V, Safadi-Safa R, et al.

    The FEBS journal 2025; (292(18)):4808-4832 doi:10.1111/febs.70098.

    PMID: 40244081
  2. 2

    Patterns of glucose hypometabolism can help differentiate FTLD-FET from other types of FTLD.

    Garcia-Guaqueta DP, Ghayal NB, Lowe VJ, et al.

    Journal of neurology 2024; (271(9)):6264-6273 doi:10.1007/s00415-024-12583-y.

    PMID: 39088063
  3. 3

    A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species.

    Benjamin-Zukerman T, Shimon G, Gaine ME, et al.

    Brain : a journal of neurology 2024; (147(11)):3890-3905 doi:10.1093/brain/awae154.

    PMID: 38743596
  4. 4

    Interoception in Parkinson's disease: A narrative review and framework for translational research.

    Longardner K, Mabry SA, Chen G, et al.

    Autonomic neuroscience : basic & clinical 2025; (259()):103258 doi:10.1016/j.autneu.2025.103258.

    PMID: 40101537
  5. 5

    An autopsy case of neuronal intermediate filament inclusion disease with regard to immunophenotypic and topographical analysis of the neuronal inclusions.

    Inoue K, Fujimura H, Ueda K, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2015; (35(6)):545-52 doi:10.1111/neup.12213.

    PMID: 26096780
  6. 6

    An autopsy case report of neuronal intermediate filament inclusion disease presenting with predominantly upper motor neuron features.

    Murakami A, Nakamura M, Nakamura Y, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2021; (41(5)):357-365 doi:10.1111/neup.12741.

    PMID: 34309938
  7. 7

    Clinical assessment of dysphagia in neurodegeneration (CADN): development, validity and reliability of a bedside tool for dysphagia assessment.

    Vogel AP, Rommel N, Sauer C, et al.

    Journal of neurology 2017; (264(6)):1107-1117 doi:10.1007/s00415-017-8499-7.

    PMID: 28470593
  8. 8

    Distinct TAF15 amyloid filament folds define multiple subtypes of FTLD-TAF15.

    Tetter S, Varghese NR, Murzin AG, et al.

    bioRxiv : the preprint server for biology 2026; doi:10.64898/2026.01.12.698957.

    PMID: 41648099
  9. 9

    Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.

    Bieniek KF, Josephs KA, Lin WL, Dickson DW

    Free neuropathology 2020; (1()):9 doi:10.17879/freeneuropathology-2020-2639.

    PMID: 34386806
  10. 10

    Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

    Jellinger KA, Korczyn AD

    BMC medicine 2018; (16(1)):34 doi:10.1186/s12916-018-1016-8.

    PMID: 29510692
  11. 11

    The psychosocial impact of childhood dementia on children and their parents: a systematic review.

    Nevin SM, McGill BC, Kelada L, et al.

    Orphanet journal of rare diseases 2023; (18(1)):277 doi:10.1186/s13023-023-02859-3.

    PMID: 37679855
  12. 12

    New evidence on the management of Lewy body dementia.

    Taylor JP, McKeith IG, Burn DJ, et al.

    The Lancet. Neurology 2020; (19(2)):157-169 doi:10.1016/S1474-4422(19)30153-X.

    PMID: 31519472
  13. 13

    Predictors of malnutrition risk in neurodegenerative diseases: The role of swallowing function.

    Pizzorni N, Ciammola A, Casazza G, et al.

    European journal of neurology 2022; (29(8)):2493-2498 doi:10.1111/ene.15345.

    PMID: 35384164
  14. 14

    Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population-based study from Latin America.

    Rodriguez Salgado AM, Acosta I, Kim DJ, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2023; (19(12)):5730-5741 doi:10.1002/alz.13384.

    PMID: 37427840

This page is for informational purposes only and does not constitute medical advice; symptom patterns and progression vary, so your neurologist and care team should guide decisions about swallowing, falls, medications, and urgent symptoms.